skip to main content

News Archive

Date: 12/12/2012
Written by: Nicole Casal Moore, 734-647-7087, [email protected] Fawcett, 734-764-2220, [email protected]
Date: 12/07/2012
Women undergoing chemotherapy who experience cognitive problems, commonly referred to as 'chemo brain,' displayed alterations in neurocognitive responses prior to undergoing treatment, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 4-8, 2012.
Date: 12/06/2012
Ponatinib acts against the most resistant types of chronic myeloid leukemia based on the results of a Phase I Trial, reported in the New England Journal of Medicine
Date: 12/05/2012
Written by Justin Harris, Phone: 734-764-2220, E-mail: [email protected].
Date: 12/05/2012
Written by Nicole Fawcett.
Date: 11/28/2012
About 70% of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Rogel Cancer Center finds.
Date: 11/12/2012
Scientists from UT Southwestern Medical Center and the University of Michigan Rogel Cancer Center have developed an innovative model for predicting the progression of skin cancer in patients.
Date: 10/30/2012
Written by Nicole Fawcett
Date: 10/17/2012
The University of Michigan Rogel Cancer Center is part of a national organization that has received $11.5 million to study sarcoma, a rare type of cancer that can occur in bones, muscle and fat.